European Clinical Trial Sites opened and Initial Dosing of Cohort 4 completed for PAS-004 Ph 1 trial January 21, 2025
Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) announced as Lead Clinical Program January 15, 2025
Development plans of NY-500, an AI-Optimized PD-1 x VEGF Bifunctional Antibody, announced in multiple oncology indications January 15, 2025
Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL January 7, 2025
First patient enrolled in Ph 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA in patients with unresectable or metastatic melanoma December 26, 2024
First patient dosed in Ph 1 trial of IMC-P115C in patients with PRAME-expressing tumors December 25, 2024
KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued December 18, 2024
Reprioritized pipeline focus on LAVA-1266 and plan to discontinue development of LAVA-1207 December 18, 2024
Efficacy threshold not achieved in Ph 1 dose escalation trial for FHD-286 + decitabine to support continued development in patients with R/R AML December 18, 2024
DSMB recommends continuation of Ph 3 study of Bria-IMT™ + an immune checkpoint inhibitor in metastatic breast cancer patients December 10, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
First Patient Enrolled in Taiwan for Ph 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC Patients December 10, 2024
First Patient Dosed in Ph 3 Clinical trial of HLX22/AC101 in 1L HER2-positive advanced gastric/GEJ cancer December 10, 2024
Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms completed in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer December 10, 2024
Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient December 4, 2024
